Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Cash & Current Investments (2022 - 2026)

TriSalus Life Sciences has reported Cash & Current Investments over the past 5 years, most recently at $56.6 million for Q1 2026.

  • For Q1 2026, Cash & Current Investments rose 335.02% year-over-year to $56.6 million; the TTM value through Mar 2026 reached $56.6 million, up 335.02%, while the annual FY2025 figure was $20.4 million, 139.75% up from the prior year.
  • Cash & Current Investments for Q1 2026 was $56.6 million at TriSalus Life Sciences, up from $20.4 million in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $56.6 million in Q1 2026 and troughed at $69182.0 in Q2 2022.
  • A 5-year average of $13.9 million and a median of $11.5 million in 2023 define the central range for Cash & Current Investments.
  • On a YoY basis, Cash & Current Investments climbed as much as 15750.93% in 2024 and fell as far as 47.21% in 2024.
  • Year by year, Cash & Current Investments stood at $9.4 million in 2022, then increased by 25.1% to $11.8 million in 2023, then dropped by 27.61% to $8.5 million in 2024, then surged by 139.75% to $20.4 million in 2025, then surged by 176.69% to $56.6 million in 2026.
  • Business Quant data shows Cash & Current Investments for TLSI at $56.6 million in Q1 2026, $20.4 million in Q4 2025, and $22.7 million in Q3 2025.